NCT05262855 - Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 2, 2022

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2025

Conditions

PDAC - Pancreatic Ductal AdenocarcinomaFAP

Interventions

DRUG

[68Ga]FAPI-46

\[68Ga\]-FAPI-46 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma (PDAC).

Trial Locations (4)

10016

NYU Langone Health, New York

49503

BAMF Health, Grand Rapids

55905

Mayo Clinic, Rochester

90095

University of California Los Angeles (UCLA) Health, Los Angeles